Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Thiopental for system suitability CRS, 10mg

Thiopental for system suitability CRS, 10mg

76-75-5

DISCOVER
OLEIC ACID CRS (2000 MG)

OLEIC ACID CRS (2000 MG)

112-80-1

DISCOVER
SULFADIAZINE FOR IDENTIFICATION OF IMPURITY F CRS (15 MG)

SULFADIAZINE FOR IDENTIFICATION OF IMPURITY F CRS (15 MG)

68-35-9

DISCOVER
METAMIZOLE IMPURITY E CRS (0.01 MG)

METAMIZOLE IMPURITY E CRS (0.01 MG)

NA

DISCOVER
HYDROCORTISONE ACETATE FOR PEAK IDENTIFICATION CRS (15 MG)

HYDROCORTISONE ACETATE FOR PEAK IDENTIFICATION CRS (15 MG)

50-03-3

DISCOVER
SAW PALMETTO EXTRACT HRS (8000 MG)

SAW PALMETTO EXTRACT HRS (8000 MG)

90106-85-7

DISCOVER
MEDROXYPROGESTERONE ACETATE FOR PEAK IDENTIFICATION CRS (25

MEDROXYPROGESTERONE ACETATE FOR PEAK IDENTIFICATION CRS (25

71-58-9

DISCOVER
RIVASTIGMINE FOR SYSTEM SUITABILITY CRS (1.01 MG)

RIVASTIGMINE FOR SYSTEM SUITABILITY CRS (1.01 MG)

129101-54-8

DISCOVER
PYRIDOSTIGMINE IMPURITY B CRS(15 MG)

PYRIDOSTIGMINE IMPURITY B CRS(15 MG)

NA

DISCOVER
BUTYL METHACRYLATE CRS (140 MG)

BUTYL METHACRYLATE CRS (140 MG)

97-88-1

DISCOVER
METHYL METHACRYLATE CRS (350 MG)

METHYL METHACRYLATE CRS (350 MG)

80-62-6

DISCOVER
2-(DIMETHYLAMINO)ETHYL METHACRYLATE CRS (150 MG)

2-(DIMETHYLAMINO)ETHYL METHACRYLATE CRS (150 MG)

2867-47-2

DISCOVER